For the Inventor, By the Inventor

Enter assignee name

Zambon Group

USPTO Granted Patents = 138

% Expired Patents = 8.7

CIPO Patents = 3

EPO Patents = 1

Trademarks = 2

Forward Citations = 971

Loading Chart...

Loading Chart...

124 inventors (with patents filed for the assignee):

Francesco Santangelo (31 out of 44 patents)

Claudio Giordano (22 out of 59 patents)

Franco Pellacini (21 out of 31 patents)

4. Gabriele Pietro Norcini (20 out of 46 patents)

5. Mauro Napoletano (19 out of 30 patents)

6. Marco Villa (18 out of 35 patents)

7. Maurizio Paiocchi (14 out of 19 patents)

8. Daniele Bonadeo (13 out of 14 patents)

9. Cesare Casagrande (13 out of 36 patents)

10. Federico Stroppolo (13 out of 15 patents)

11. Gabriele Morazzoni (12 out of 14 patents)

12. Dario Chiarino (12 out of 33 patents)

13. Annibale Gazzaniga (12 out of 14 patents)

14. Stefania Montanari (10 out of 11 patents)

15. Angelo Carenzi (10 out of 24 patents)

Core Competencies:

Macrolide Compounds

Anti-Inflammatory Activity

Phosphodiesterase Inhibitors

Pharmaceutical Compositions

Cardiovascular Agents

Antimycotic Compounds

Thiamphenicol Derivatives

Oxidative Stress

Nitroalkenes

Gabapentin

Heavy Metal Removal

Erythromycin Derivatives

138 patents: Sort by Forward Citations

1. 7704960 - Macrolide compounds endowed with antiinflammatory activity (2010-04-27),

2. 7507721 - Macrolides with antiinflammatory activity (2009-03-24),

3. 7488811 - Macrolide compounds endowed with antiinflammatory activity (2009-02-10),

4. 7265251 - Process for the preparation of nitroalkenes (2007-09-04),

5. 7199266 - Process for the preparation of gabapentin (2007-04-03),

6. 6894164 - Process for the preparation of (pyridinylidene)-phthalides (2005-05-17),

7. 6833389 - Use of thiamphenicol and derivatives thereof for the preparation of pharmaceutical compositions useful in the treatment of Chlamydia pneumoniae infections (2004-12-21),

8. 6706882 - Process for the preparation of (pyridinylidene)-phthalides (2004-03-16),

9. 6627659 - Methods of decreasing the effects of oxidative stress using N-acetylcysteine (2003-09-30),

10. 6589993 - Treating vancomycin-intermediates and multiresistant staphylococci infection with thiamphenicol or a salt thereof (2003-07-08),

11. 6589951 - Phthalazine derivatives as phosphodiesterase 4 inhibitors (2003-07-08),

12. 6548480 - Phosphonic acid derivatives with metallopeptidase inhibitory activity (2003-04-15),

13. 6525055 - Tricyclic phthalazine derivatives as phosphodiesterase 4 inhibitors (2003-02-25),

14. 6498160 - Phthalazine derivatives as phosphodiesterase 4 inhibitors (2002-12-24),

15. 6492360 - Phthalazine derivatives phosphodiesterase 4 inhibitors (2002-12-10),

Zambon Group, headquartered in Vicenza, Italy, specializes in the development and manufacturing of pharmaceutical products, particularly focusing on macrolide compounds. The company is engaged in innovative research across various therapeutic areas, including anti-inflammatory agents, phosphodiesterase inhibitors, and cardiovascular treatments. Zambon also explores the potential of antimycotic compounds and thiamphenicol derivatives, addressing oxidative stress and its implications in health, thereby contributing significantly to the pharmaceutical landscape.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

138 Patents

#2 in Vicenza

#64 in Italy

#5,854 in the World

Zambon Group

Forward Citations = 971

124 inventors:

Francesco Santangelo (31 out of 44 patents)

Claudio Giordano (22 out of 59 patents)

Franco Pellacini (21 out of 31 patents)

4. Gabriele Pietro Norcini (20 out of 46 patents)

5. Mauro Napoletano (19 out of 30 patents)

Please report any incorrect information to [email protected]

Loading…